Literature DB >> 3208459

Renal failure and nephrotic syndrome associated with sulindac.

P J Champion de Crespigny1, G J Becker, B U Ihle, N M Walter, C A Wright, P Kincaid-Smith.   

Abstract

Four elderly patients developed nephrotic syndrome while receiving sulindac. Sulindac treatment had commenced 4-12 months prior to presentation with the nephrotic syndrome. Two patients also developed oliguric renal failure. Renal biopsy in one showed minimal change nephropathy and in three cases membranous nephropathy. Interstitial nephritis was present on renal biopsy in all cases. The nephrotic syndrome and renal failure resolved in all cases after withdrawal of sulindac. Two patients received steroid therapy and improvement in renal function and disappearance of proteinuria seemed to be temporarily related to steroid therapy in both cases. Despite the fact that sulindac is less likely to cause renal failure due to inhibition of renal prostaglandin secretion this report shows that sulindac treatment can be associated with renal failure and the nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208459

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

Review 1.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

Review 2.  Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs. Evidence of a common mechanism.

Authors:  U Ravnskov
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

3.  Sildenafil Induced Acute Interstitial Nephritis.

Authors:  Ryan Burkhart; Nina Shah; Matthew Lewin
Journal:  Case Rep Nephrol       Date:  2015-09-27

4.  A case of severe nephrotoxicity associated with long-term dietary supplement use.

Authors:  Farrukh M Koraishy; Gilbert W Moeckel; David S Geller
Journal:  Clin Nephrol       Date:  2017-08-02       Impact factor: 0.975

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.